XLXiangdong Liu

Xiangdong Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiangdong Liu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta‐Analysis

    by Mingjie Yuan, Shuyi Han, Yanfei Jia, Jiankai Feng, Duanrui Liu, Zhenguo Su, Xiangdong Liu

    Statins are associated with gastric cancer (GC) risk. The present study aimed to clarify the efficacy of statins on the overall survival (OS) benefits in patients with GC. Publications were retrieved from PubMed, Embase, and the Cochrane Library as of April 2022. Data from the eligible cohort, case‐control studies, and randomized control trials (RCTs) were extracted for the meta‐analysis. Hazard ratio (HR) and 95% confidence intervals (CI) were used to assess the association between statins users and OS in GC patients. Subgroup analysis was performed based on the study design (prospective vs. retrospective). A total of 6 studies encompassing 5693 GC patients were included. Statins added to the standard treatment prolonged the patient’s OS outcome (HR (95% CI): 0.72 (0.53–0.97), p = 0.032; I2 = 88.0%, pheterogeneity < 0.001). A prospective study did not find any statistically significant difference in OS between statins users vs. nonstatin users (HR (95% CI): 0.92 (0.68–1.26), p = 0.614; I2 = 11.7%, pheterogeneity = 0.322), whereas the retrospective studies showed prolonged OS in statins users (HR (95% CI): 0.63 (0.42–0.961), p = 0.032; I2 = 94.6%, pheterogeneity < 0.001). Statin users had significantly improved OS compared to nonstatin users in GC treatment. This long‐term survival benefit was only observed in the pooled analysis of retrospective studies but not in prospective studies.


  • Open Access

    Role of platelet infiltration as independent prognostic marker for gastric adenocarcinomas

    by Jing Wang, Miao Zhang, Ting Zhou, Shengmei Zhao, Zhenguo Su, Xiangdong Liu

    Background: In recent years, the relationship between malignant tumors and platelets has been paid more attention. The increase of platelets is an independent risk factor for the poor prognosis of some malignant tumors. Methods: This study retrospectively analyzed the clinical and pathological data of 114 patients with initial gastric cancer from August 2005 to August 2018 in Shandong Provincial Hospital. Single‐factor and multifactor survival analysis were used to evaluate the effect of platelet elevation on postoperative survival. The gastric cancer tissues of the Jinan Central Hospital and its matched paracancerous tissues were collected. The expression of platelets in tissues was detected by immunofluorescence technique. Different numbers of platelets were co‐cultured with MKN‐45 cells, CCK‐8 assay and transwell assay were performed, and the expression of epithelial‐mesenchymal transition‐related proteins was detected. Results: Platelet count was independent factors affecting prognosis. The stratified analysis showed that there was a statistically significant difference in the 5‐year survival rate between the platelet‐increase group and the normal platelet group in the TNM stages I‐II. The expression of platelets in gastric cancer tissues was higher than that in adjacent tissues. The results of CCK‐8 and transwell showed that platelets significantly enhanced the proliferation and metastasis capability of MKN‐45 cells in a concentration‐dependent manner. After co‐culture, the expression level of E‐cadherin protein in MKN‐45 cells decreased, and the protein expression levels of N‐cadherin, vimentin, and VEGFA increased. Conclusion: Platelet elevation is closely related to the occurrence, development, and metastasis of gastric cancer, and platelet count can be used as a prognostic indicator for malignant tumors.


  • Open Access

    Analytical comparison between two hematological analyzer systems: Mindray BC‐5180 vs Sysmex XN‐1000

    by Jing Wang, Shengmei Zhao, Zhenguo Su, Xiangdong Liu

    Background: To compare the Mindray BC‐5180 and Sysmex XN‐1000 instruments by analyzing the results of complete blood count in the external quality assessment in Shandong Province in 2018.Methods: In the external quality assessment, 10 batches of quality control materials were issued throughout the year. The test items were WBC, RBC, Hb, PLT, and HCT. The laboratories using Mindray BC‐5180 and Sysmex XN‐1000 were screened, and the results were analyzed by t test, Passing‐Bablok regression analysis, and Bland‐Altman analysis.Results: Thirty‐six laboratories using Mindray BC‐5180 instruments and thirty‐six laboratories using Sysmex XN‐1000 instruments were screened, and the average difference between the two instruments results is not significant (P > 0.05, t test). Passing‐Bablok regression analysis showed that the 95% confidence interval of the regression equation interception of each test item included 0, and the 95% confidence interval of the slope contained 1, r > 0.98, which showed that the correlation is good. The Bland‐Altman analysis showed that both instruments had more than 95% of the points within the 95% consistency limit (WBC97.2%, RBC95.6%, PLT97.2%, Hb96.7%, HCT97.5%). Within the consistency limit, the absolute value of the difference between the Mindray BC‐5180 instrument and the Sysmex XN‐1000 instrument is WBC 0.14%, RBC 0.26%, PLT 2.7%, and Hb 1.9%. HCT is 0.69%, and the difference is clinically acceptable.Conclusion: It can be considered that the two instruments have good correlation and consistency, and the two instruments can replace each other.


  • Open Access

    Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics

    by Xiangdong Liu, Yan Zheng, Chuanwu Qiao, Fei Qv, Jingnan Wang, Butong Ding, Yuping Sun, Yunshan Wang

    Special AT-rich sequence binding protein 1 (SATB1) is found acting as a “genome organizer” that functions as a landing platform to regulate tissue-specific gene ex-pression. In breast cancer cell lines it has been proven that SATB1 could upregulate the expression of the HER2. In this paper, the relevance of SATB1 and HER2 expression was assessed in human breast cancer tissues, and their influence on tumor histological grade and patients’ survival was explored. Using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), 169 patients with breast cancer were assessed for SATB1 expression, HER2 amplification and hormone-receptor (HR) expression. The effects of SATB1 expression on HER2 and HR expression as well as their association with clinicopathologic characteristics were further analyzed by statistical evaluation. SATB1 expression was correlated with HER2 expression in breast cancer(r = 0.191; p = 0.013). SATB1, HER2 and SATB1/HER2 co-expression was negatively correlated with HR expression (r = −0.228, p = 0.003; r = −0.338, p = 0.000; r = −0.527, p = 0.000, respectively). SATB1 and HER2 single positive and their co-expression were all significantly correlated with higher histological grade (r = 0.239, p = 0.002; r = 0.160, p = 0.038; r = 0.306, p = 0.003, respectively). Multivariate cox regression analyses showed that SATB1 and HER2 were independent risk factors for breast cancer patients, while HR was a protective factor for patients’ survival. Comparing to SATB1 or HER2 single positive expression, SATB1/HER2 co-expression tended to have even worse prognosis. SATB1 and HER2 performed a synergistic effect in breast cancer. Their expression correlated with poorly differentiated breast cancer and indicated an unfavorable prognosis. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1400555050159723 .